Stock MDGL MADRIGAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
193.3 USD -0.54% Intraday chart for Madrigal Pharmaceuticals, Inc. -8.82% -16.44%
Apr. 22 BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
Apr. 22 BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT

Evolution of the average Target Price on Madrigal Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3fba9d76845ad8a.rrQFd-Ti_ruS_Ayhs1lZ7FSxsK3P52i0IWIJawQOqrU.3O5NGrWztfPbyjvk3msK2QD-0vS1vj3kSAReJGs86-zHmU4DgteR4sXKZw~7a521ef17f9d12824e67c8ab5a7de895

Analyst Recommendations on Madrigal Pharmaceuticals, Inc.

BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing MT
Evercore ISI Raises Price Target on Madrigal Pharmaceuticals to $405 From $325, Maintains Outperform Rating MT
Madrigal commences $500 million public offering of common stock RE
TD Cowen Adjusts Madrigal Pharmaceuticals' Price Target to $390 From $349, Maintains Outperform Rating MT
Citigroup Adjusts Madrigal Pharmaceuticals' Price Target to $389 From $382, Maintains Buy Rating MT
JMP Securities Adjusts Price Target on Madrigal Pharmaceuticals to $397 From $351, Maintains Market Outperform Rating MT
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $375 From $320, Maintains Outperform Rating MT
H.C. Wainwright Adjusts Price Target on Madrigal Pharmaceuticals to $425 From $405, Maintains Buy Rating MT
B. Riley Upgrades Madrigal Pharmaceuticals to Neutral From Sell After FDA Approval of Rezdiffra, Raises PT to $270 From $155 MT
HC Wainwright Adjusts Madrigal Pharmaceuticals' Price Target to $405 From $275, Maintains Buy Rating MT
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $320 From $300, Maintains Outperform Rating MT
B. Riley Downgrades Madrigal Pharmaceuticals to Sell From Neutral, Says Nearly All Stock Scenarios Point to Higher Likelihood of Downside; Adjusts PT to $155 From $204 MT
B. Riley Downgrades Madrigal Pharmaceuticals to Sell From Neutral, Cuts Price Target to $155 From $204 MT
Piper Sandler Adjusts Price Target on Madrigal Pharmaceuticals to $336 From $305, Maintains Overweight Rating MT
Jefferies Cuts Madrigal Pharmaceuticals Price Target to $321 From $340, Maintains Buy Rating MT
B. Riley Raises Madrigal Pharmaceuticals' PT to $204 From $154 on Increased Resmetirom Pricing Guidance, Keeps Neutral Rating MT
HC Wainwright Adjusts Madrigal Pharmaceuticals' Price Target to $275 From $225, Maintains Buy Rating MT
B. Riley Slashes Price Target on Madrigal Pharmaceuticals to $154 From $224, Neutral Rating Kept MT
Fed rates at 7%: Is it on the cards? Our Logo
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
193.3 USD
Average target price
377.1 USD
Spread / Average Target
+95.04%
High Price Target
565 USD
Spread / Highest target
+192.25%
Low Price Target
150 USD
Spread / Lowest Target
-22.41%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Madrigal Pharmaceuticals, Inc.

BofA Securities
Evercore ISI
TD Cowen
Citigroup
JMP Securities
B. Riley
HC Wainwright
Oppenheimer
Piper Sandler
Jefferies & Co.
Canaccord Genuity
UBS
SVB Securities LLC
Goldman Sachs
BMO Capital
Chardan

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MDGL Stock
  4. Consensus Madrigal Pharmaceuticals, Inc.